Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Anai

Showing results (171-180 of 175) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 175 results.
Cancer Research and Treatment|June 27, 2025
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 StudySe Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Urologic Oncology|October 5, 2023
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairmentKeita Minami, Takahiro Osawa, Takahiro Kojima, et al.
Cancer Science|May 14, 2020
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinomaTakahiro Osawa, Takahiro Kojima, Tomohiko Hara, et al.
Pageof 18

Showing results (171-180 of 175) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 175 results.
Cancer Research and Treatment|June 27, 2025
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 StudySe Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.
Urologic Oncology|October 5, 2023
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairmentKeita Minami, Takahiro Osawa, Takahiro Kojima, et al.
Cancer Science|May 14, 2020
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinomaTakahiro Osawa, Takahiro Kojima, Tomohiko Hara, et al.
Pageof 18